This study evaluated the feasibility and potential efficacy of a yoga intervention for patients with NSCLC and their caregivers.
Impact of language barrier and patient ethnicity on time interval from diagnosis to treatment for patients with NSCLC was measured at a public hospital and a private hospital.
In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.
PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.
Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy
[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.
Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.
This case demonstrates that, although rare, spontaneous TLS can occur even in the absence of chemotherapy, and a high index of suspicion for the effect should be maintained when patients with malignancies demonstrate the classic symptom of laboratory abnormalities.
Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.
Significant increases seen in heart rate and arterial stiffness were observed in the first 30 minutes after smoking electronic-cigarette containing nicotine.
An investigation into the challenges of lung cancer clinical trials found that despite a lack of participants being detrimental to successful trial completion, clinical trials are trending toward increasing their eligibility criteria, making it more difficult to accrue enough eligible participants.
Vitamin B intake appears to be related to lung cancer risk, but only for men or male smokers.
A retrospective analysis showed an association between depth of response (DepOR) and greater overall survival and longer progression-free survival.
[Lung Cancer: Targets and Therapy] This research reviews the current literature on psychosocial interventions in lung cancer, and discusses .
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
Contrary to some concerns, persons at high risk for lung cancer who undergo CT lung scans are more likely to attempt smoking cessation regardless of their test results compared with unscreened persons.
A recent study demonstrated that eating a diet high in saturated fats and low in polyunsaturated fats may increase a person's risk of developing lung cancer.
The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.
An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
E-cigarettes used with nicotine-based liquid have the same potential to produce cancer-causing DNA damage as unfiltered regular cigarettes.
Doses May Be Adjusted for Treating NSCLC Patients
Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.
Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.
The design of cigarette filters with ventilation is associated with rising adenocarcinoma rates, research indicates.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.
A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.
Risk for cardiac events linked to RT for locally advanced NSCLC, especially in patients with a history of cardiac disease or receiving higher RT doses.
Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.
A free lung cancer screening program in Augusta, Georgia, found more than double the lung cancer rate of previous screenings.
Patients were more comfortable with their decisions about lung cancer screening after a shared decision-making visit.
Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.
Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.
A study of a large, diverse patient population appears to show an increasing incidence of lung cancer in patients who have never smoked tobacco.
Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.
A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.
Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
E-cigarettes and replacement nicotine therapy deposit fewer harmful chemicals in the body that smoking.
Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.
Annual lung cancer screening of only high-risk smokers more cost-effective than current methods.
Researchers estimate that out of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only a fraction received it.
There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.
A higher consumption of nuts was associated with a lower overall risk for developing lung cancer irrespective of smoking status.
Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015
The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.
Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.
Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.
Study found 21 percent of those with late-stage non-small cell lung cancer went without therapy, even though it could boost survival.
Annual counseling could reduce prevalence and prevent many smoking-attributable fatalities.
Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.
Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.
Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.
[Cancer Informatics] This research examinbed independent and joint performance of retrieving smoking status through different sources and compared the performance of retrieving smoking strength information from narrative text and PPI.
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma
[OncoTargets and Therapy] The surgical approach that offers the best outcomes for malignant pleural mesothelioma management is still debated. This research examines the efficacy of surgical treatment.
Carboplatin-paclitaxel with concurrent RT has comparable efficacy with cisplatin-etoposide plus RT in patients with stage III NSCLC.
The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.
Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.
A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.
Among patients with non-small cell lung cancer (NSCLC), those with a mental health disorder appeared to have a higher risk of death.
IH-induced exosomes from mice significantly promote TC1 malignant properties, according to a recent study.
In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.
Researchers report on their evaluation of the efficacy and safety of vandetanib, a kinase inhibitor of VEGFR, EGFR, and the RET-tyrosine kinase, in patients with NSCLC tumors with chromosomal rearrangements involving RET.
This study focused on determining the effectiveness of a short-term high-intensity interval training (HIIT) program to improve patients' cardiorespiratory fitness prior to NSCLC resection.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Atezolizumab (Tecentriq) is approved by the FDA for the treatment of metastatic NSCLC in specific cases or tumors with EGFR or ALK gene mutations.
The addition of pembrolizumab to carboplatin and pemetrexed improves overall response rate compared with chemotherapy alone and has a manageable safety profile in patients with newly diagnosed advanced nonsquamous NSCLC.
Treatment with the kinase inhibitor lenvatinib demonstrated promising activity in patients with RET-positive NSCLC.
Changes in depression symptoms over time are associated with differences in survival among patients with lung cancer, especially those with early stage disease.
Patient understanding of lung cancer screening increased after participation in focus groups.
IMRT was associated with lower rates of severe pneumonitis and cardiac doses compared with 3D-CRT in patients with locally advanced NSCLC.
An analysis of population trends in England demonstrated that use of electronic cigarettes improves the rate of successful quit attempts, but results in less use of prescription nicotine-replacement therapy products.
Adding WBRT to dexamethasone and best supportive care provides little additional benefit for patients with NSCLC and brain metastases who are ineligible to undergo resection or stereotactic radiotherapy.
The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.
Hypoxia-activated prodrugs prevented treatment resistance in a mathematical model of EGFR mutation-driven non-small cell lung cancer (NSCLC).
Longer overall survival was achieved with TKIs targeting EGFR mutations in non-small cell lung cancer (NSCLC) patients.
Patients with metastatic non-small cell lung cancer demonstrated prolonged median progression-free survival with the administration of erlotinib below the maximum tolerated dose.
A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
For nonsolid nodules identified by CT screening for lung cancer, annual screening with low-dose CT can eliminate the need for biopsy or surgery.
Lung cancers that manifest as nonsolid nodules seem to have indolent course, according to recent research data.
Undergoing pleurectomy and decortication for malignant pleural mesothelioma generally leads to improved quality of life after the surgery.
Breath analysis offers an option for both primary screening and postsurgery monitoring of patients with lung cancer. Exhaled breath has certain carbonyl VOCs that indicate the presence of lung cancer in a process researchers hope will receive FDA approval.
Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.
Fourteen percent to 25% of patients with lung cancer also have autoimmune disease. This comorbidity could make them unsuitable candidates for immunotherapy.
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.
Cigarette smoking is more common among survivors of AYA cancer than those without cancer, and smoking is associated with greater comorbidities and poorer general health.
Biochemical Marker Is a Better Predictor of Adverse Effects in Patients with Non-small Cell Lung Cancer
Albumin concentration with an established cutoff point is proven a better predictor of both chemotherapy toxicity and survival in patients with advanced lung cancer.
Most family physicians report discussing low-dose CT imaging with patients at high risk for lung cancer, but referrals for screening remain low, a study published in the journal Cancer has shown.
A decreasing number of adolescents are smoking, but e-cigarette use and rates of distracted driving are on the rise for this group.
[Lung Cancer: Targets and Therapy] This research evaluates the addition of bevacizumab to standard chemotherapy as well as with the use of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM).
The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
[Lung Cancer: Targets and Therapy] In this research, a literature review identifies international guidelines associated with non-small-cell lung cancer (NSCLC) recurrence useful as remedies in postoperative follow-up.
Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer
When more quality measures are incorporated into patient care, survival rates for patients with stage IIIA non-small cell lung cancer (NSCLC) increase, but only 13% of eligible patients actually receive all 4 recommended quality measures.
Results from this study showed that 5-year survival for older patients after surgery for lung cancer is favorable. Based on these results, surgeons might be better equipped to individualize care for this older population.
Increased Risk of Noncancer Deaths Associated with Stereotactic Body Radiation Therapy for Lung Cancer
High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.
Video-assisted thoracoscopic surgery (VATS) is associated with less postoperative pain and better quality of life than anterolateral thoracotomy for the first year of surgery in patients with stage I NSCLC.
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer
[Cancer Management and Research] This research examines the use of proactive GI AE management strategies for patients with non-small-cell lung cancer being treated with ceritinib.
The most benefit from adding necitumumab to chemotherapy with gemcitabine and cisplatin occurred for patients whose advanced squamous NSCLC expressed EGFR.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Breast Implants Associated With Increased Risk of Breast Anaplastic Large-cell Lymphoma
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Comparison of Survival Outcomes Between Radical Hysterectomy and Definitive Radiochemotherapy in Stage IB1 and IIA1 Cervical Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|